HRT and Breast Cancer: What Survivors and High-Risk Women Should Know

Medically reviewed by Maybell Nieves, M.D. · Written by Carrie Madormo, RN, MPH · September 11, 2026

Get trusted info about menopause and connect with women who get it.

Key Takeaways

For people who have had breast cancer or have a family history of it, the safety of hormone replacement therapy (HRT) depends on personal health history and the type of hormone therapy used.
For most people who have had breast cancer, doctors generally advise against systemic hormone therapy like pills or patches, though low-dose vaginal estrogen may still be an option for some. Research shows that estrogen combined with a progestin carries a higher breast cancer risk than estrogen alone, and that risk can increase the longer the therapy is used.
Talking with your healthcare team, including your cancer doctor, is an important step toward understanding which options may work best for your specific situation, and bringing questions and your medical history to those appointments can help guide the conversation.

If you’ve had breast cancer or it runs in your family, you may wonder whether hormone replacement therapy (HRT) is safe for you.

Hormone therapy works well for menopause symptoms such as hot flashes, night sweats, and vaginal dryness. Whether HRT is safe for you depends on factors such as your personal and family health history and the type of hormone therapy.

For most women who have had breast cancer, doctors advise against systemic hormone therapy, such as pills or patches. For women at higher risk of breast cancer who have never had it, hormone therapy may still be an option. Here’s what to know about each situation.

🗳️ Have you talked with a doctor about breast cancer risk and hormone therapy for menopause symptoms?

Yes, and it was helpful.

Yes, but it wasn’t helpful.

No, but I plan to.

No, and I don’t plan to.

What To Know About HRT and Breast Cancer Risk

Here’s a brief overview of what the research and guidelines say about common situations:

You have had breast cancer — Doctors usually advise against systemic therapy, such as pills and patches. There may be exceptions based on your situation.
You have had breast cancer and have vaginal dryness — Low-dose vaginal estrogen may still be an option, particularly if nonhormonal treatments haven’t helped. Talk with your healthcare team about the benefits and risks.
Breast cancer runs in your family — Family history alone usually doesn’t rule out hormone therapy. Your healthcare team can help you weigh your benefits and risks.
You’re considering estrogen alone versus estrogen plus a progestin — Estrogen alone does not seem to raise breast cancer risk with short-term use. Estrogen plus a progestin can increase risk after three to five years of use.
You want to know what the research says — Results from the Women’s Health Initiative showed that increased breast cancer risk with estrogen plus a progestin was fewer than 1 additional case per 1,000 women each year.
You’re wondering if the risk lasts forever — Breast cancer risk linked to estrogen-progestin therapy drops after you stop treatment. However, some increased risk may remain for years.

How Hormone Replacement Therapy Affects Breast Cancer Risk

Two factors matter most: which hormones you take and how long you take them.

If you still have your uterus, you generally shouldn’t take systemic estrogen by itself. Estrogen alone makes the lining of the uterus grow too thick, which increases the risk of endometrial cancer. Doctors usually add a second hormone, called a progestogen, to protect the uterus.

This means women with a uterus who use systemic estrogen usually also need a progestogen. This combination is also linked to a higher breast cancer risk than estrogen alone. Here’s what to know:

Estrogen alone may not increase risk — In the Women’s Health Initiative, estrogen alone was not linked to a higher breast cancer risk after about seven years of use. Some observational studies have found that risk may increase with longer use.
Estrogen plus a progestin can increase risk — Breast cancer risk does not appear to increase with short-term use, according to the American Cancer Society. After four years of use, the risk goes up in women over 60 and increases more after 10 years of use.
The type of HRT matters — Much of the strongest research comes from studies of specific types and doses of hormones, so the findings may not apply equally to every product. Breast cancer risk may vary with the hormones used, the dose, the form, and length of use, as well as your health.
Mammograms may be harder to read — Some types of HRT can make breast tissue dense, which can make a tumor harder to see. In the Women’s Health Initiative, breast cancers diagnosed in women taking estrogen plus a progestin were more likely to be larger and diagnosed at a later stage.

What To Know If You Have Had Breast Cancer

The advice on HRT after breast cancer depends on the type of hormone therapy and your situation.

Pills and Patches Are Usually a No

The Menopause Society advises against HRT that treats your whole body — pills, patches, gels, and sprays — for women who have had breast cancer.

There may be exceptions. If your hot flashes and night sweats are severe and nothing else has helped, hormone therapy may be worth discussing. That conversation should include your cancer doctor, not just your regular doctor or gynecologist.

You May Read Headlines That Sound Reassuring

Some research reports sound like good news. One large study from Denmark followed women treated for early breast cancer and found no increased risk of the cancer coming back or of death.

Here’s the catch: Studies like this are called observational studies, which means researchers watch what happens rather than assigning women to a treatment. Women who receive hormone therapy may differ from those who don’t in ways that affect the results.

Randomized controlled trials, in which participants are randomly given a therapy, provide stronger evidence about whether a treatment causes a particular outcome. Those studies have raised concerns that systemic hormone therapy may increase the risk of breast cancer coming back, which is why guidelines generally advise against it after breast cancer.

Vaginal Estrogen Is a Different Story

Vaginal dryness, painful sex, and frequent urinary infections have their own treatment options. If nonhormone approaches haven’t helped, low-dose vaginal estrogen or dehydroepiandrosterone (DHEA) may be an option because very little estrogen reaches the bloodstream. Talk with your cancer doctor before using these treatments.

One group needs extra care. If your breast cancer was hormone receptor-positive and you take an aromatase inhibitor, your healthcare team may be more cautious about using vaginal estrogen. That decision should involve your cancer doctor.

Having Another Hormone-Sensitive Cancer Also Matters

Cancer experts advise against hormone therapy after some hormone-sensitive cancers, including advanced uterine cancer, uterine sarcoma, and two kinds of ovarian cancer (endometrioid and low-grade serous).

For some other cancers, the benefits of hormone therapy may outweigh the risks. These may include most epithelial ovarian cancers, early-stage uterine cancer, and cervical cancer.

Women with a BRCA1 or BRCA2 gene mutation (change) or Lynch syndrome who have never had breast cancer may also be able to use hormone therapy.

Cancer is not one disease. The type and stage of cancer can change the answer. If you have a copy of your pathology report, bring it with you to your appointments.

If You Are at Higher Risk but Never Had Cancer

Many women are told that breast cancer in the family rules out hormone therapy. Usually, it does not. On their own, these factors do not necessarily rule out hormone therapy:

Breast cancer in your family
Ovary removal surgery because of a BRCA1 or BRCA2 mutation
A history of benign (noncancerous) breast changes or conditions

This does not make hormone therapy an automatic yes. You still need a personalized plan. Two details can help guide the discussion with your doctor:

The combination of estrogen plus a progestin carries more breast cancer risk than estrogen alone.
Very little low-dose vaginal estrogen reaches the bloodstream. Its effect on cancer risk is less clear than that of systemic hormone therapy.